EP3013327A1 — Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
Assigned to Hanmi Pharmaceutical Co Ltd · Expires 2016-05-04 · 10y expired
What this patent protects
Disclosed are a capsule composite formulation for preventing or treating erectile dysfunction and benign prostatic hyperplasia comprising tadalafil and tamsulosin, and a method of preparing the same. The capsule composite formulation of the present invention enables the complete …
USPTO Abstract
Disclosed are a capsule composite formulation for preventing or treating erectile dysfunction and benign prostatic hyperplasia comprising tadalafil and tamsulosin, and a method of preparing the same. The capsule composite formulation of the present invention enables the complete separation of the two pharmaceutically active ingredients and minimizes reactivity between the active ingredients, and thus provides excellent product stability over time, thereby maximizing the therapeutic effects thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.